16 September 2026 editorial review · Item
AVAnT1A (early COVID-19 vaccination, GPPAD primary prevention): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: AVAnT1A is primary prevention in genetically at-risk infants, not demonstrated efficacy. Vaccine licensure for infection is not a T1D indication; no outcome upgrade.
- Registry NCT06452654: RECRUITING; updated 2025-09-23; enrollment 2252 (ESTIMATED); primary completion 2027-10 (ESTIMATED); results not posted in retrieved record.